Recombinant clonal stable CHO cell line constitutively expressing full length human CD20 protein, also known as MS4A1 (Genbank #NM_152866). Surface expression of CD20 was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of CD20 [removed]High, Medium) to mimic different stages of cancer target cells with various CD20 expression levels.
Mycoplasma testing: This cell line has been screened using the MycoAlert Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination. MycoAlert Assay Control Set (Lonza, #LT07-518) was used as a positive control.
Host Species: hamster
Supplied as Each vial contains ~ 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.
Background
CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. Although the functional significance of CD20 is not clear, and CD20 has no known ligands, CD20 has been shown to regulate intracellular calcium levels. CD20 is a highly attractive target antigen for immunotherapy because it is expressed on more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an Essential Medicine.Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin s lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). Additionally, more recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.
Application
Useful as CD20-expressing target cells in co-culture assays with CD20-CAR-T cells for CD20-specific cell killing assays.
Host Cell
CHO
Uniprot
P11836
Species
Human
Synonyms
rituximab
Shipping Temperature
-80°C (dry ice)
Note
LICENSE DISCLOSURE: Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit the use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of Biohippo products to your laboratory. Biohippo does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [email protected] for details. Publications using this cell line should reference Biohippo Inc. Warning: Avoid freeze/thaw cycles.
Storage Stability
Store in liquid nitrogen immediately upon receipt.
Reference
1. Kosmas, C, et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 2002; 16: 2004-20152. Cragg, MS, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005; 8: 140-1743. Martyniszyn, A, et al. CD20-CD19 bispecific CAR T cells for the treatment of B cell malignancies. Hum Gene Ther. 2017 Dec; 28(12): 1147-11574. Lee, SY, et al. Preclinical optimization of a CD20-specific chimeric antigen receptor vector and culture conditions. J Immunother. 2018 Jan; 41(1): 19-31